CU20200038A7 - Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 - Google Patents

Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3

Info

Publication number
CU20200038A7
CU20200038A7 CU2020000038A CU20200038A CU20200038A7 CU 20200038 A7 CU20200038 A7 CU 20200038A7 CU 2020000038 A CU2020000038 A CU 2020000038A CU 20200038 A CU20200038 A CU 20200038A CU 20200038 A7 CU20200038 A7 CU 20200038A7
Authority
CU
Cuba
Prior art keywords
pyrazolo
pyrimidine
inhibitors
pirrolo
diona
Prior art date
Application number
CU2020000038A
Other languages
English (en)
Inventor
Dr Mico Bräuer
Lames Lindsay Carr
Ursinyova Nina Connelly
Adam James Davenport
Dr Oliver Martin Fischer
Dr Marcus Koppitz
Dr Jens Nagel
Dr Poland Neuhaus
Shelley Anne Parrott
Dr Elisabeth Pook
Dr Andrea Rotgeri
Dr Holger Siebeneicher
Robert James Townsend
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20200038A7 publication Critical patent/CU20200038A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La invención se refiere a compuestos derivados de pirazolo-pirrolo-pirimidin-diona de la fórmula general (I)</p> <p>(ESPACIO PARA LA FORMULA)</p> <p>en la cual R1, R2 y R3 son como se los define en las reivindicaciones. Dichos compuestos de fórmula (I) son inhibidores del receptor P2X3 útiles para el tratamiento o la profilaxis de enfermedades asociadas con dicho receptor, en particular trastornos neurogénicos.</p>
CU2020000038A 2017-10-27 2018-10-18 Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3 CU20200038A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27
PCT/EP2018/078567 WO2019081343A1 (en) 2017-10-27 2018-10-18 NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

Publications (1)

Publication Number Publication Date
CU20200038A7 true CU20200038A7 (es) 2021-03-11

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000038A CU20200038A7 (es) 2017-10-27 2018-10-18 Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3

Country Status (26)

Country Link
US (1) US11319324B2 (es)
EP (1) EP3700907B1 (es)
JP (1) JP7250011B2 (es)
KR (1) KR20200078567A (es)
CN (1) CN111527090B (es)
AU (1) AU2018354777A1 (es)
BR (1) BR112020008122B1 (es)
CA (1) CA3080249A1 (es)
CL (1) CL2020001107A1 (es)
CO (1) CO2020005065A2 (es)
CR (1) CR20200174A (es)
CU (1) CU20200038A7 (es)
DK (1) DK3700907T3 (es)
DO (1) DOP2020000100A (es)
EA (1) EA202091003A1 (es)
EC (1) ECSP20023626A (es)
ES (1) ES2914377T3 (es)
IL (1) IL274036A (es)
JO (1) JOP20200100A1 (es)
MA (1) MA50439A (es)
MX (1) MX2020004981A (es)
NI (1) NI202000031A (es)
PE (1) PE20200932A1 (es)
PH (1) PH12020550494A1 (es)
SG (1) SG11202003662XA (es)
WO (1) WO2019081343A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
US12703701B2 (en) * 2019-12-10 2026-08-11 Shanghai Hansoh Biomedical Co., Ltd. Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
MX2023014525A (es) * 2021-06-09 2024-01-29 Shanghai Hansoh Biomedical Co Ltd Forma salina y cristal del derivado policiclico que contiene pirazol, y metodo de preparacion del mismo y uso del mismo.
WO2023021328A1 (en) * 2021-08-17 2023-02-23 Bellus Health Cough Inc. Preparation of a p2x3 antagonist
EP4713327A1 (en) * 2023-05-17 2026-03-25 Insilico Medicine IP Limited Spiro derivatives as wrn inhibitors
US20250230168A1 (en) * 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025261355A1 (en) * 2024-06-20 2025-12-26 Insilico Medicine Ip Limited Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869789A (en) 1988-07-21 1990-02-19 Upjohn Company, The Pyrazolo-pyrrolo-pyrimidine-diones
US5843951A (en) * 1995-09-28 1998-12-01 Otsuka Pharmaceutical Factory Inc. Analgesic composition of pyrazolo(1,5-A) pyrimidines
JP2003513909A (ja) 1999-11-05 2003-04-15 ワーナー−ランバート・カンパニー Ａｃａｔ阻害剤によるプラーク破裂の予防
US7511050B2 (en) 2006-06-23 2009-03-31 Incyte Corporation Purinone derivatives as HM74A agonists
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
US9260425B2 (en) * 2011-08-12 2016-02-16 Genetech, Inc. Pyrazolo[3,4-c]pyridine compounds and methods of use
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
SG11201505446WA (en) * 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP2021500380A (ja) 2021-01-07
ECSP20023626A (es) 2020-06-30
JOP20200100A1 (ar) 2020-05-06
IL274036A (en) 2020-06-30
EP3700907B1 (en) 2022-03-09
SG11202003662XA (en) 2020-05-28
CR20200174A (es) 2020-06-26
BR112020008122B1 (pt) 2022-11-01
CA3080249A1 (en) 2019-05-02
MA50439A (fr) 2021-05-19
PH12020550494A1 (en) 2021-01-11
MX2020004981A (es) 2020-08-24
CO2020005065A2 (es) 2020-05-29
DOP2020000100A (es) 2020-09-15
CL2020001107A1 (es) 2020-10-23
US11319324B2 (en) 2022-05-03
EA202091003A1 (ru) 2020-09-11
BR112020008122A2 (pt) 2020-11-03
ES2914377T3 (es) 2022-06-10
CN111527090B (zh) 2023-05-26
PE20200932A1 (es) 2020-09-17
CN111527090A (zh) 2020-08-11
NI202000031A (es) 2020-08-28
JP7250011B2 (ja) 2023-03-31
AU2018354777A1 (en) 2020-04-16
US20210317128A1 (en) 2021-10-14
DK3700907T3 (da) 2022-05-30
EP3700907A1 (en) 2020-09-02
KR20200078567A (ko) 2020-07-01
WO2019081343A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CL2018001230A1 (es) Tratamiento de osteoartritis
MX2017003695A (es) Pirimidinonas como inhibidores del factor xia.
CO2018008173A2 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2017001152A2 (es) Espirocicloheptanos como inhibidores de la cinasa rho (rock)
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
MX2017014956A (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares.
MX2020004504A (es) Derivados de fenoximetilo.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
MX377610B (es) Agonistas del receptor de glucagon.
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
UY37018A (es) Inhibidores bicíclicos de pad4
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
EA201692143A1 (ru) Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.